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Background: Prolonged early antibiotics in extremely premature infants may have negative 
effects. We aimed to assess prevalence and outcomes of provision of prolonged early antibiotics to 
extremely premature infants in the absence of culture-confirmed infection or NEC.
Methods: Cohort study of infants from 13 centers born without a major birth defect from 
2008-2014 who were 401-1000 grams birth weight, 22-28 weeks gestation, and survived ≥5 days 
without culture-confirmed infection, NEC, or spontaneous intestinal perforation. We determined 
the proportion of infants who received prolonged early antibiotics, defined as ≥5 days of antibiotic 
therapy started at ≤72 hours of age, by center and over time. Associations between prolonged early 
antibiotics and adverse outcomes were assessed using multivariable logistic regression.
Results: A total of 5730 infants were included. The proportion of infants receiving prolonged 
early antibiotics varied from 30-69% among centers and declined from 49% in 2008 to 35% in 
2014. Prolonged early antibiotics was not significantly associated with death (adjusted odds ratio 
1.17 [95% CI, 0.99-1.40], p=0.07) and was not associated with NEC.
Conclusions: The proportion of extremely premature infants receiving prolonged early 
antibiotics decreased, but significant center variation persists. Prolonged early antibiotics was not 
significantly associated with increased odds of death or NEC.
INTRODUCTION
Antibiotics are the most common medications prescribed for infants in the neonatal intensive 
care unit (NICU) (1). Although the incidence of culture-confirmed early-onset sepsis (EOS) 
in term infants is relatively low (~0.5-0.8 cases/1000 live births), both the incidence of 
disease (15-19 cases/1000) and EOS-attributable mortality (3.5% vs 35%) are substantially 
higher among very low birth weight, preterm infants (2). Given the high mortality associated 
with EOS, presence of maternal and neonatal risk factors, and time required for pathogens to 
be isolated in culture, empirical antibiotics targeting EOS are administered to large 
proportions of infants in the NICU (3,4).
In 2009, the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development Neonatal Research Network (NRN) reported data from 1998-2001 suggesting 
that prolonged duration of antibiotics administered soon after birth to extremely low birth 
weight (ELBW, birth weight <1000 g) infants was associated with increased risk of death, 
necrotizing enterocolitis (NEC), and the composite measure of NEC or death (5). In that 
study, 53% of 4039 infants surviving >5 days were administered antibiotics beginning at 
birth and extending ≥5 days in the absence of culture-confirmed infection. These findings 
were consistent with other smaller studies (6,7). It is unclear to what degree neonatal 
clinicians have changed antibiotic practice over the ensuing 20 years and the impact on 
infant outcomes. A recent study including 40,534 very low birth weight (VLBW, <1500 g) 
infants born at 297 primarily nonteaching centers found a small but significant decrease in 
the rate of prolonged early antibiotic administration among VLBW infants, but no change 
among the subgroup of 14,923 ELBW infants (8). The purpose of this study was to 1) 
describe changes over time in the provision of prolonged early antibiotic therapy without 
culture-confirmed infection or intraabdominal inflammatory process, and 2) describe 
associations of such prolonged early antibiotic therapy with adverse outcomes among a more 
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contemporary cohort of extremely premature infants cared for at academic centers of the 
NRN.
MATERIALS AND METHODS
Subjects
This was a retrospective analysis of data entered into a registry of high-risk preterm infants 
maintained by the NRN. Study infants were born between January 1, 2008, and December 
31, 2014. The registry contains maternal and neonatal information from the intrapartum 
period until infant discharge home, transfer from the primary center, death, or 120 days after 
birth. Limited demographic, clinical, and outcome data, including whether or not infants 
were started on antibiotics before and continued beyond the first 5 postnatal days, were 
collected by trained research staff utilizing a standardized manual of operations. Site 
participation differed over the study period, and we included data from the 13 centers that 
participated in the NRN for the entire study period (denoted with an asterisk in the 
Acknowledgments). Infants were included in the study if they had a birth weight of 
401-1000 g and gestational age of 22 0/7 – 28 6/7 weeks. Exclusion criteria were: death <5 
days after birth; blood or cerebrospinal fluid culture obtained within the first 5 postnatal 
days growing pathogenic bacterial or fungal species; NEC or spontaneous intestinal 
perforation (SIP) diagnosed ≤5 days after birth; or major birth defect. The institutional 
review board at each center approved participation in the registry.
Definitions
Prolonged early antibiotic therapy was defined as ≥5 days of antibiotic administration 
initiated at ≤72 hours of age. Comparator infants may have had antibiotics initiated within 
72 hours of age and discontinued before 5 days, or may not have had antibiotics initiated 
within 72 hours of age. Small for gestational age (SGA) was defined as birth weight <10th 
percentile for sex and gestational age using percentiles reported by Alexander et al (9). Late-
onset sepsis (LOS) was defined as a blood and/or cerebrospinal fluid culture obtained at >72 
hours of age and growing a recognized bacterial or fungal pathogen if the infant was 
administered antibiotics for ≥5 days or until death. NEC was defined as modified Bell’s 
stage ≥IIA (10,11).
Statistical analysis
Prior to excluding infants who died at <5 days or who had a positive culture, NEC, or SIP in 
the first 5 days, we determined the proportion of infants with EOS by center. After 
exclusions, we determined the proportion of infants who received prolonged early antibiotics 
overall and by center over time. We compared infant demographic and maternal 
characteristics between infants who received prolonged early antibiotics and those who did 
not using Student’s t-test for continuous variables and Wald chi-square test for categorical 
variables. P-values were 2-tailed with values ≤0.05 considered statistically significant. 
Analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
Separate logistic regression models were used to evaluate associations between birth year, 
center, and receipt of prolonged early antibiotics; and between prolonged early antibiotics 
Greenberg et al. Page 3
Pediatr Res. Author manuscript; available in PMC 2019 July 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and outcomes, including all-cause mortality after 5 days of life, NEC, LOS, LOS due to 
organisms other than coagulase-negative staphylococci (non-CoNS LOS), and LOS due to 
one or more fungal organisms (fungal LOS). We examined death and composite outcomes of 
death/morbidity for all infants; NEC and LOS were examined in survivors to discharge to 
reduce potential bias due to different at-risk periods, particularly for infants with short 
survival times. All models included birth year (categorical), study center, infant 
characteristics (gestational age, SGA, sex, and 5-minute Apgar score <5), and maternal 
characteristics (black race, multiple birth, rupture of membranes >24 hours, receipt of 
antenatal steroids, perinatal antibiotic therapy, hypertension, antepartum hemorrhage, and 
cesarean section).
Because prolonged early antibiotics may be administered to more severely ill infants at 
greater risk for adverse outcomes, we also included an indicator in our models aimed at 
identifying severity of illness. We defined this indicator as initiation of any mechanical 
ventilation on the day of birth and continued use for all of the first 7 days after birth, or for 
all days until death if death occurred before 7 days (continuous mechanical ventilation 
[cMV]). We examined whether associations between prolonged early antibiotics and adverse 
outcomes were different among infants with and without this indicator by including the 
interaction between prolonged early antibiotics and cMV in our models. Results are shown 
separately for the cMV and non-cMV groups if this interaction was significant at p≤0.10. 
Otherwise, results shown are based on models that did not include the cMV interaction.
RESULTS
The NRN registry enrolled 14,212 infants from 2008-2014. Of these, 5730 met all study 
inclusion and exclusion criteria (Supplemental Digital Content S1). Prolonged early 
antibiotics were administered to 2526/5730 (44%) infants. Multiple maternal and neonatal 
characteristics differed significantly between infants who did or did not receive prolonged 
early antibiotics (Table 1). Overall, infants who received prolonged early antibiotics were 
younger and smaller, had lower 5-minute Apgar scores, were less likely to have been born 
via cesarean section, were more likely to have been born to a mother with prolonged rupture 
of membranes or who was treated with antenatal antibiotics, and were more likely treated 
with cMV (Table 1).
Factors associated with receipt of prolonged early antibiotics
The overall percentage of infants treated with prolonged early antibiotics decreased from 
49% in 2008 to 35% in 2014 (adjusted odds ratio [aOR] 0.44 [95% CI, 0.35-0.56], p<0.001) 
(Supplemental Digital Content S2, Table 2). The percentage of infants treated varied by 
center, ranging from 30-69% (Figure 1). The center-specific incidence of EOS ranged from 
0.3-3.6%. The center-specific rate of prolonged early antibiotic administration decreased 
over the study period at 8 of the 13 centers. Compared to the center with the lowest rate, 
infants cared for at 11 of the 12 remaining centers were significantly more likely to receive 
prolonged early antibiotics (Table 2).
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Relationship of prolonged early antibiotics with outcomes
Infants who received prolonged early antibiotics had marginally but not significantly higher 
odds of death compared to those who did not receive prolonged early antibiotics (19% vs 
13%, aOR 1.17 [95% CI, 0.99-1.40], p=0.07). Prolonged early antibiotics were not 
significantly associated with the composite outcomes of death or specific morbidities (Table 
3), nor with specific morbidities among survivors to discharge. These findings were not 
different among infants who did or did not receive cMV, with one exception: the relationship 
of prolonged early antibiotics with LOS caused by fungal organisms varied by cMV group 
(interaction p<0.001) (Table 3). Among infants not treated with cMV, prolonged early 
antibiotic administration was associated with increased odds of fungal LOS (2% vs 0.4%, 
aOR 4.95 [95% CI, 1.93-12.69], p<0.001) (Table 3).
DISCUSSION
We observed a significant decline in the overall use of prolonged early antibiotics among 
ELBW infants cared for in 13 NRN centers over a 7-year period. The overall use of 
prolonged early antibiotic therapy during this study was lower (44% vs 53%) than that 
reported in our prior study of early antibiotic use in infants born 1998-2001. However, we 
observed persistent significant center-specific antibiotic practice variation. The proportion of 
infants treated with prolonged early antibiotics differed between centers, and reduction in 
prolonged therapy was only observed at 8 of the 13 centers. The rates of prolonged antibiotic 
administration remained 10-to-100-fold higher than the rates of culture-confirmed EOS, 
even with the observed decrease in prolonged therapy. In contrast to our prior NRN study, 
we found no statistically significant association between prolonged early antibiotics and risk 
of death. Our study raises several issues to be considered as neonatal caregivers work to 
identify the best approaches to use of antibiotics for medically fragile, extremely premature 
infants in the first postnatal days.
Our findings reflect slowly evolving views of the role of antibiotics in neonatal care. 
Multiple national organizations recommend comprehensive approaches to antimicrobial 
stewardship (12), and neonatal providers are actively pursuing approaches to optimize 
antibiotic use among NICU patients (13). In a study using the Pediatric Health Information 
System database, antibiotic utilization decreased ~5% per year from 2004 to 2012 among 
hospitals without mandatory public reporting requirements for central line-associated 
bloodstream infection (14); similar secular trends in NICU antibiotic use were observed 
among hospitals subject to such reporting requirements. Neonatal antimicrobial stewardship 
programs at individual centers and collaboratives also report success in safely decreasing 
overall NICU antibiotic utilization (15-17). However, NICUs care for infants across a wide 
spectrum of gestational ages and morbidities, and studies focused specifically on VLBW and 
ELBW infants report mixed outcomes. The Premier Perspective Database study measured 
quarterly rates of antibiotic initiation and duration among 40,364 VLBW infants cared for in 
297 centers across the United States from 2009-2015 (8). No significant trends were 
observed for antibiotic initiation, but declines were noted for prolonged early antibiotics 
among VLBW (but not ELBW) infants. The Canadian Neonatal Network (CNN) reported 
decreased antibiotic use in VLBW infants between 2010 and 2014, a finding that coincided 
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with decreased rates of LOS (18). Despite this decline, the study still found an overall 20% 
antibiotic utilization rate among VLBW infants in the absence of culture-confirmed 
infection or NEC. Single-site studies further illustrate the challenges of antibiotic 
optimization among premature infants. Guidelines for use of antibiotics targeting highly 
antibiotic-resistant pathogens (e.g., meropenem, vancomycin) resulted in more appropriate 
antibiotic use in one Canadian NICU, but improvements were not seen among VLBW 
infants (19). A comprehensive antibiotic stewardship program in a large American NICU did 
not significantly decrease overall antibiotic utilization, although some changes were 
observed in the use of specific antibiotics such as ampicillin and vancomycin (20). Viewed 
from the perspective of the many challenges in optimizing neonatal antibiotic 
administration, the decline in prolonged early antibiotic administration we observed in the 
current study (14% absolute change, 28% relative change) among ELBW infants without a 
corresponding statistically significant rise in subsequent mortality, LOS, or NEC is clinically 
significant.
One important issue raised by our study is whether there is a critical level, duration, or 
timing of antibiotic exposure at which antibiotics administered in the absence of proven 
infection begin to cause harm. In contrast to prior findings from the NRN and other centers 
(6,21), we found no significant association between prolonged early antibiotics and NEC. 
Multiple practice differences over the past 20 years may have contributed to this finding, 
including changes in the use of mothers’ own milk, human donor milk, and probiotic 
supplements, and we did not collect detailed information on those factors. Our findings do 
suggest, however, that the association of empiric antibiotic use and risk of NEC has declined 
as overall antibiotic use has declined. The multicenter CNN study also suggests that the 
magnitude of antibiotic exposure may be associated with the magnitude of antibiotic-related 
harm (18). Increased exposure to antibiotics over an infant’s entire hospital stay was 
associated with increased adjusted odds of a composite outcome of mortality and major 
morbidities, with the greatest risk associated with the highest quartile of antibiotic exposure. 
The prior NRN study noted increased odds of death per day of antibiotic therapy (OR=1.16 
[95% CI, 1.08-1.24]), and a substantial proportion of infants received therapy for ≥10 days 
(5). In the current study, neither duration of antibiotics nor daily antibiotic exposure data 
were recorded, and it is possible that our findings reflect an even larger magnitude of 
decreased antibiotic use than we have measured.
We continue to find substantial center variation in the use of prolonged early antibiotics 
(range of 30-69% from 2008-2014 compared to 27-85% in 1998-2001). This variation 
appeared to be unrelated to the incidence of EOS at each site. It is unlikely to be due to a 
corresponding variation in severity of illness, as each NRN site is an academic, tertiary care 
center caring for relatively large numbers of extremely premature infants. Schulman and 
colleagues also found wide variation in California NICU antibiotic use unexplained by 
variation in proven infection, NEC, surgical volume, or mortality (22). We speculate that 
center variation in this early postnatal clinical practice represents true elective practice 
differences that reflect provider uncertainty regarding the risks and benefits of antibiotics 
administered in the absence of proven infection. In our cohort, simply being born at one 
academic center instead of another could increase an infant’s odds of receiving prolonged 
early antibiotics sevenfold, even after adjustment for demographic and clinical factors. Our 
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findings underscore an imperative for individual centers to track antibiotic utilization and to 
compare such data with other institutions. Robust mechanisms for sharing and receiving 
such data, including membership in voluntary neonatal networks, will facilitate efforts to 
improve local practices.
Potentially unjustified variation may matter. While not statistically significant, receipt of 
prolonged early antibiotics was associated with marginally increased odds of death in our 
cohort of infants (aOR 1.17 [95% CI, 0.99-1.40]). An OR >1.0 is consistent with the 
previous NRN report, which showed an aOR of 1.46 (95% CI, 1.19-1.78) for prolonged 
therapy (5). Although our analysis cannot fully account for differences in severity of illness 
among infants who do and do not receive prolonged early antibiotics, the potential for 
mediating harm remains of concern. The association between prolonged early antibiotics 
and fungal LOS in survivors to discharge may be an example of harm rather than 
confounding by indication. In this instance, relative harm was associated with prolonged 
early antibiotic administration to infants who were clearly less severely ill (those whose 
caregivers did not decide to use cMV) compared to those who were more severely ill (those 
who were treated with cMV). Broad-spectrum antibiotic use has been previously associated 
with invasive candidiasis in premature infants (23,24), although why such use might 
differentially affect those of less illness severity, defined by available data describing degree 
of respiratory support, remains unclear. We speculate that less severely ill infants had fewer 
risk factors for fungal LOS and thus risk was increased significantly due to the use of 
prolonged antibiotics; more severely ill infants may have already had maximized risk of 
fungal LOS due to other factors. Increased perinatal and postnatal exposure to antibiotics in 
premature infants has been associated with alterations in the gut microbiome, and may 
provide some insight into the biologic mechanisms by which prolonged antibiotic 
administration may be harmful in the absence of confirmed infection (25,26). It is possible 
that dysbiosis leads to proliferation of potential pathogens and predisposition to later 
infection, with resulting increases in morbidity and mortality (27). In addition, antibiotic 
exposure has been associated with a reduction in gastric bacterial colonization, which could 
increase risk for infection and increase feeding intolerance (28). Regardless of the potential 
mechanisms of harm or magnitude of harm, our findings support ongoing efforts to limit 
empiric antibiotic administration to ELBW infants at highest risk of infection and to spare 
those who may be at lowest risk of EOS, such as those born by cesarean section, without 
labor or maternal chorioamnionitis (29).
The strengths of our study include the large sample size of extremely preterm infants, 
uniform definitions and data collection over time, and observation of trends over time and 
across multiple regions in the United States. The retrospective analysis limits our ability to 
measure variables other than those routinely collected in the NRN database. We attempted to 
account for clinical severity by adjusting for mechanical ventilation, but we were unable to 
calculate validated severity scores such as the CRIB II or SNAPPE-II (30,31). While we 
excluded infants with culture-confirmed sepsis in the first 5 postnatal days, we were unable 
to identify infants who may have had other true infections, such as neonatal pneumonia. We 
did not have data regarding the type or timing of quality improvement interventions or 
antibiotic stewardship programs at participating centers. Finally, while our study was similar 
to the previous NRN study, several differences limit comparisons between the two reports. 
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The previous study included infants diagnosed with NEC or SIP in the first 5 days after 
birth, while we excluded these infants (Supplemental Digital Content S1). Our rationale was 
that antibiotic administration to those infants is not discretionary, and infants with NEC and 
SIP are likely to justifiably receive prolonged early antibiotics and have increased likelihood 
of mortality and morbidity. The previous NRN study included expanded data collection that 
detailed the exact days of exposure and the type of antibiotics prescribed on each day. This 
level of detail was not available to the current study. In the earlier NRN study, even 4 days of 
early antibiotics was associated with NEC, death, as well as the composite outcome; but in 
the current study, we were unable to examine the effect of antibiotics administered for >48 
hours but <5 days, and the risk of this practice remains unclear. We also do not know what 
proportion of infants had no antibiotics given in the first 72 hours after birth (~2-3% had 
none given in the prior study) (5), and we do not know what proportion of infants were 
administered cephalosporins, antibiotics that are associated with higher mortality and 
Candida infections (24,32).
CONCLUSION
In this study of 5730 infants across 13 NRN centers, the proportion of infants who received 
prolonged early antibiotics in the absence of EOS, NEC, or SIP decreased significantly 
between 2008 and 2014. Overall prolonged antibiotic use also declined in comparison to a 
prior NRN study that included infants born between 1998 and 2001. Prolonged early 
antibiotic exposure continues to vary widely across NRN centers. Our findings support 
ongoing efforts to promote neonatal antibiotic stewardship, as supported by the Centers for 
Disease Control and Prevention (33). Such efforts must include robust means of identifying 
those infants who will derive maximum benefit and minimum harm from antibiotic 
treatments that will be acceptable across different sites of neonatal care.
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Figure 1. 
Percentage of study infants receiving prolonged early antibiotic therapy and percentage of 
infants with early-onset sepsis (EOS) by center.
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Table 1.
Demographics and clinical characteristicsa
Prolonged
early
antibiotics
(N=2526)
No prolonged
early
antibiotics
(N=3204)
P-value
Infant characteristics
 Birth weight, g (median, IQR) 730 (615, 850) 790 (670, 890) <0.001
 Gestational age, weeks (median, IQR) 25 (24, 26) 26 (25, 27) <0.001
 By gestational age week <0.001
  22 1% 1%
  23 11% 6%
  24 23% 15%
  25 24% 21%
  26 20% 23%
  27 13% 21%
  28 7% 14%
 Small for gestational age 11% 11% 0.48
 Male 51% 46% <0.001
 5-minute Apgar <5 24% 17% <0.001
 Mechanically ventilated for first 7 days of lifeb 55% 33% <0.001
Maternal characteristics
 Race/ethnicityc 0.19
  Black 45% 43%
  White 36% 38%
  Hispanic 13% 14%
  Other 6% 5%
 Multiple birth 23% 26% 0.01
 Hypertension 26% 37% <0.001
 Antenatal steroids 89% 91% 0.05
 Antenatal antibiotics 76% 71% <0.001
 Rupture of membranes >24 hours 28% 18% <0.001
 Antepartum hemorrhage 19% 18% 0.84
 Cesarean section 64% 73% <0.001
IQR=interquartile range
a
Information was missing as follows: maternal race/ethnicity, 16 infants; maternal hypertension, 8 infants; antepartum hemorrhage, 5 infants; 
antenatal steroids, 12 infants; antenatal antibiotics, 34 infants; timing of rupture of membranes, 159 infants; cesarean delivery, 3 infants; 5-minute 
Apgar score, 14 infants; mechanical ventilation, 1 infant.
b
This group includes 40 infants who were intubated continuously until death before day 7.
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c
Maternal race/ethnicity was defined as non-Hispanic white, non-Hispanic black, Hispanic (both white and black), and other race (Asian/Pacific 
Islander, American Indian / Alaska native, more than one race, other not specified). Those of white or black race with missing ethnicity information 
(5.3% of blacks, 0.9% of whites) were classified as non-Hispanic.
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Table 2.
Differences in receipt of prolonged early antibiotic therapy by birth year and center adjusting for neonatal and 
maternal characteristics
Adjusted odds ratio
(95% confidence interval)
P-value
Birth year (reference: 2008)
 2009 0.89 (0.72-1.10) 0.29
 2010 1.02 (0.82-1.27) 0.83
 2011 0.79 (0.63-0.98) 0.03
 2012 0.58 (0.47-0.72) <0.001
 2013 0.58 (0.47-0.73) <0.001
 2014 0.44 (0.35-0.56) <0.001
Center (reference: Center 1)
 2 1.16 (0.90-1.50) 0.26
 3 1.42 (1.10-1.83) 0.008
 4 1.78 (1.33-2.39) <0.001
 5 1.61 (1.14-2.27) 0.007
 6 2.24 (1.53-3.28) <0.001
 7 1.61 (1.20-2.16) 0.002
 8 1.81 (1.34-2.43) <0.001
 9 2.17 (1.67-2.82) <0.001
 10 2.97 (2.20-4.01) <0.001
 11 3.07 (2.26-4.17) <0.001
 12 5.46 (4.03-7.39) <0.001
 13 7.36 (5.18-10.46) <0.001
Infant characteristics
 Gestational age, weeks (reference: 28)
  22 1.81 (0.96-3.41) 0.07
  23 2.54 (1.86-3.47) <0.001
  24 1.98 (1.54-2.55) <0.001
  25 1.74 (1.38-2.20) <0.001
  26 1.40 (1.11-1.76) 0.004
  27 1.06 (0.83-1.34) 0.66
 Small for gestational age 1.65 (1.35-2.01) <0.001
 Male 1.15 (1.03-1.29) 0.02
 5-minute Apgar <5 1.38 (1.19-1.61) <0.001
 Mechanically ventilated for entire first 7 days of life 1.79 (1.57-2.05) <0.001
Maternal characteristics
 Black race 1.24 (1.08-1.41) 0.002
 Multiple birth 0.90 (0.78-1.04) 0.16
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Adjusted odds ratio
(95% confidence interval)
P-value
 Hypertension 0.78 (0.67-0.91) 0.001
 Antenatal steroids 0.82 (0.66-1.02) 0.07
 Antenatal antibiotics 1.18 (1.01-1.37) 0.03
 Rupture of membranes >24 hours 1.84 (1.59-2.14) <0.001
 Antepartum hemorrhage 0.83 (0.71-0.97) 0.02
 Cesarean section 0.84 (0.73-0.97) 0.02
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Table 3.
Outcomes for infants who received prolonged early antibiotic therapy versus those who did not
Outcome, n (column %) Prolonged
early
antibiotics
No prolonged
early
antibiotics
Adjusted OR for
outcome (95% CI)
prolonged early
antibiotics vs no
prolonged early
antibiotics
P-value
All infants who survived ≥5 days 2526 3204
 Death before discharge 466 (19) 409 (13) 1.17 (0.99-1.40) 0.07
 Death or NEC 623 (25) 635 (20) 1.08 (0.93-1.25) 0.34
 Death or LOS 1008 (40) 1082 (34) 0.98 (0.86-1.12) 0.76
 Death or non-CoNS LOS 662 (26) 677 (21) 1.01 (0.87-1.17) 0.89
 Death, NEC, or LOS 1086 (43) 1204 (38) 0.97 (0.86-1.11) 0.66
Infants who survived to discharge 2055 2787
 NEC 157 (8) 225 (8) 0.91 (0.72-1.15) 0.43
 LOS 540 (26) 670 (24) 0.90 (0.77-1.05) 0.18
 Non-CoNS LOS 195 (10) 268 (10) 0.84 (0.67-1.04) 0.11
 Fungal LOSa
  cMV group 23 (2) 22 (3) 0.64 (0.33-1.23) 0.18
  Non-cMV group 21 (2) 8 (0.4) 4.95 (1.93-12.69) <0.001
OR=odds ratio; CI=confidence interva; NEC=necrotizing enterocolitis; LOS=late-onset sepsis; CoNS=Coagulase-negative Staphylococcus; 
cMV=continuous mechanical ventilation for first 7 days.
a
The interaction between prolonged early antibiotics and the continuous mechanical ventilation group was significant at p<0.001, and therefore the 
adjusted ORs are reported separately.
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